Back to search
FDAFDA · Food and drugs·Recall number D-1364-2020

Metformin HCl Extended Release Tablets, USP, 500 mg, Generic for Glucophage XR, Pkg Size 100, Mfg: Time-Cap, Labs Inc., Farmingdale, NY, Preferred Pharmaceuticals, Anaheim, CA NDC: 68788-6932-01

Published July 8, 2020 · Recall initiated: June 17, 2020

Summary

FDA records drug Class II recall D-1364-2020, published July 8, 2020 and initiated June 17, 2020. Recalling firm: Preferred Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 144 bottles; Lot: J0119M, K1419L, K2719J, A0220H; Exp. Date 12/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Preferred Pharmaceuticals, Inc.
Distributor
Product was distributed to two medical clinics located in FL.
Lot
J0119M, K1419L, K2719J, A0220H; Exp. Date 12/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metformin HCl Extended Release Tablets, USP, 500 mg, Generic for Glucophage XR, Pkg Size 100, Mfg: Time-Cap, Labs Inc., Farmingdale, NY, Preferred Pharmaceuticals, Anaheim, CA NDC: 68788-6932-01 recalled?

Yes. FDA published recall D-1364-2020 on July 8, 2020. Reported hazard: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter